109.50Open109.50Pre Close0 Volume1 Open Interest150.00Strike Price0.00Turnover112.78%IV2.20%PremiumDec 20, 2024Expiry Date103.91Intrinsic Value100Multiplier9DDays to Expiry5.59Extrinsic Value100Contract SizeAmericanOptions Type0.9986Delta0.0001Gamma2.44Leverage Ratio-0.0270Theta0.0390Rho2.44Eff Leverage0.0019Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet